Table 3.

Pooled relative risk and 95% confidence interval from meta-analyses.

	N (I2)	Fixed-Effects Model	Random-Effects Model
Total cardiovascular disease
Statins	14 (30.0%)	0.81 (0.78–0.85)	0.81 (0.76–0.86)
Atorvastatin	4 (55.5%)	0.83 (0.78–0.88)	0.83 (0.76–0.91)
Fluvastatin	1 (NA)	0.48 (0.24–0.94)	0.48 (0.24–0.94)
Lovastatin	1 (NA)	0.76 (0.63–0.91)	0.76 (0.63–0.91)
Pravastatin	7 (28.8%)	0.81 (0.74–0.89)	0.77 (0.67–0.89)
Rosuvastatin	1 (NA)	0.80 (0.55–1.16)	0.80 (0.55–1.16)
Omega-3	13 (0%)	0.98 (0.95–1.01)	0.98 (0.95–1.01)
Overall	27 (59.6%)	0.92 (0.90–0.94)	0.89 (0.85–0.94)
Coronary heart disease
Statins	7 (0%)	0.69 (0.62–0.77)	0.70 (0.62–0.77)
Atorvastatin	1 (NA)	0.60 (0.49–0.75)	0.60 (0.49–0.75)
Lovastatin	1 (NA)	0.76 (0.62–0.92)	0.76 (0.62–0.92)
Pravastatin	3 (0%)	0.69 (0.56–0.84)	0.69 (0.56–0.84)
Rosuvastatin	1 (NA)	0.75 (0.58–0.96)	0.75 (0.58–0.96)
Simvastatin	1 (NA)	0.67 (0.11–3.95)	0.67 (0.11–3.95)
Omega-3	10 (0%)	0.90 (0.84–0.96)	0.90 (0.85–0.96)
Overall	17 (44.6%)	0.84 (0.79–0.88)	0.81 (0.75–0.89)
Myoca rdial infarction
Statins	27 (51.4%)	0.74 (0.69–0.79)	0.69 (0.61–0.78)
Atorvastatin	7 (73.6%)	0.79 (0.71–0.87)	0.70 (0.55–0.89)
Fluvastatin	2 (42.6%)	1.40 (0.76–2.56)	1.18 (0.40–3.46)
Lovastatin	2 (0%)	0.62 (0.45–0.85)	0.62 (0.45–0.85)
Pitavastatin	1 (NA)	0.37 (0.10–1.39)	0.37 (0.10–1.39)
Pravastatin	8 (3.1%)	0.68 (0.60–0.77)	0.66 (0.56–0.78)
Rosuvastatin	4 (62.9%)	0.74 (0.64–0.86)	0.71 (0.55–0.91)
Simvastatin	3 (11.2%)	0.82 (0.43–1.56)	0.85 (0.41–1.78)
Omega-3	15 (45.6%)	0.88 (0.82–0.94)	0.89 (0.80–0.99)
Overall	42 (53.8%)	0.81 (0.77–0.85)	0.78 (0.72–0.85)
Stroke
Statins	26 (33.3%)	0.84 (0.80–0.89)	0.85 (0.79–0.92)
Atorvastatin	7 (64.9%)	0.88 (0.79–0.98)	0.88 (0.71–1.10)
Fluvastatin	2 (11.4%)	0.75 (0.17–3.31)	0.77 (0.13–4.38)
Pravastatin	9 (0%)	0.88 (0.80–0.96)	0.88 (0.80–0.96)
Rosuvastatin	4 (68.8%)	0.81 (0.70–0.95)	0.80 (0.60–1.07)
Simvastatin	3 (0%)	0.76 (0.67–0.85)	0.76 (0.67–0.85)
Omega-3	13 (36.1%)	1.02 (0.94–1.10)	0.88 (0.71–1.10)
Overall	39 (46.2%)	0.90 (0.86–0.94)	0.91 (0.85–0.98)